Axogen, Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- AxoGen, Inc. (NASDAQ: AXGN) develops and commercializes surgical solutions for peripheral nerve regeneration and repair; its comprehensive product portfolio includes Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa extracellular matrix product used to wrap and protect damaged peripheral nerves; AxoGuard HA+ Nerve Protector, a porcine submucosa extracellular matrix base layer coated with a proprietary hyaluronate-alginate gel to enhance nerve gliding and provide short- and long-term protection; AxoGuard Nerve Cap, a porcine submucosa extracellular matrix product that protects peripheral nerve ends to reduce symptomatic neuroma formation; and Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft used to protect and separate tissues during surgical repair. Founded in 2002 and headquartered in Alachua, Florida, the company serves reconstructive plastic surgeons, hand surgeons, orthopedic surgeons, oral and maxillofacial surgeons, and other healthcare providers treating traumatic injuries, breast reconstruction, nerve decompression, oral/maxillofacial procedures, and pain management; its products address over 900,000 annual procedures in a market exceeding $2.7 billion and are available in the United States, Canada, the United Kingdom, South Korea, and select European and international markets. In December 2025, AxoGen received FDA approval of its Biologics License Application for Avance Nerve Graft (arwx), transitioning the product from human cells, tissues, and cellular/tissue-based classification to a regulated biologic with 12 years of market exclusivity; the approval follows the RECON pivotal study completion and supports expanded commercialization. Recent financial performance reflects strong growth, with Q3 2025 revenue of $60.1 million, up 23.5% year-over-year, double-digit increases across all markets, raised full-year 2025 guidance to at least $222.8 million (19% growth), gross margins of 73-75%, and expectations for net cash flow positivity; payer coverage expansions added 18.1 million lives in 2025, reaching over 64% commercial coverage.
Company News
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
GMED or AXGN: Which Is the Better Value Stock Right Now?
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)
Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
Axogen Inc (AXGN) Shares Fall 3.0% -- GF Value Says Still Overvalued
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair
2 Medical-Device Stocks Lighting Up the Options Pits
Axogen, Inc. (AXGN) M&A Call Transcript
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
Axogen Inc (AXGN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 64/100
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More
Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel
AxoGen (NASDAQ:AXGN) Shares Gap Down Following Weak Earnings
Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
AxoGen Q2 Earnings Call Highlights
AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates